Archive for January 2018
New Big Data Study From MIT Puts Clinical Trial Success Rate at 14 Percent
Nearly 14 percent of all drugs in clinical trials eventually win approval from the FDA — a much higher percentage than previously thought, according to a new study from the MIT Sloan School of Management. Source: Drug Industry Daily
Read MoreAAM: Exclusionary Biologics Contracts Will Hurt Emerging Biosimilars Market
The Association for Accessible Medicines’ Biosimilars Council submitted an amicus brief supporting Pfizer in its antitrust lawsuit against Johnson & Johnson, arguing the company’s practices will keep biologics prices high and limit competition from biosimilars. Source: Drug Industry Daily
Read MoreDemocrats Ask GAO to Review White House Action on Opioids Since Emergency Declaration
Eighteen Democratic senators joined Health, Labor, Education and Pensions Committee Ranking Member Patty Murray (Wash.) in calling on the Government Accountability Office to review the Trump administration’s efforts against the opioid addiction crisis. Source: Drug Industry Daily
Read MoreFDA Proposes Packaging Reductions to Curb Opioid Addiction
The FDA proposed a new tactic in its fight against the opioid epidemic — blister packs of smaller quantities of opioid drugs that could give providers better prescription options, especially for drugs like Vicodin and Percocet usually intended for short-term use. Source: Drug Industry Daily
Read MoreTexas Drugmaker Warned for Misbranded Products
The FDA warned Young Health Products for marketing drug products on its website that are not safe and effective for their promoted uses. Source: Drug Industry Daily
Read MoreGet Ready for the M&A Explosion
A look at whether the new tax reform will really spur a M&A spending spree for drugmakers. Source: BioSpace
Read MoreMeet the Unnoticed Alzheimer's Biotech Facing a Make-or-Break 2018
It seems that the primary news surrounding Alzheimer’s disease research has been nothing but negative for years. Source: BioSpace
Read MoreOn a Roll: Sage Shows Off Early-Stage Insomnia Data
The new data supports further development of SAGE-217 in disorders associated with disruption of normal sleep. Source: BioSpace
Read More3 Big Drugmakers With Huge Catalysts on the Horizon
A look at three big biotech companies that have big catalysts this year that could have a, you guessed it, big effect. Source: BioSpace
Read MoreWhy AbbVie Could Join the M&A Mania Soon
The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace
Read More